Cencora, Inc. (NYSE:COR) Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,542 shares of the company's stock after purchasing an additional 1,305 shares during the period. CIBC Asset Management Inc's holdings in Cencora were worth $9,101,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Pacer Advisors Inc. raised its holdings in Cencora by 6,855.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after purchasing an additional 2,035,679 shares during the period. Wellington Management Group LLP grew its position in Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after acquiring an additional 338,452 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Cencora by 40.2% during the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after buying an additional 308,773 shares during the period. Two Sigma Advisers LP boosted its position in shares of Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after buying an additional 292,600 shares during the period. Finally, State Street Corp raised its stake in shares of Cencora by 3.8% during the third quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after acquiring an additional 291,867 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, Robert W. Baird upped their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and an average price target of $277.90.

Cencora Price Performance

COR traded down $1.99 on Friday, hitting $241.47. 1,060,827 shares of the company were exchanged, compared to its average volume of 1,488,495. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The business's fifty day moving average is $239.34 and its 200 day moving average is $237.46. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The firm has a market capitalization of $46.83 billion, a P/E ratio of 34.35, a price-to-earnings-growth ratio of 1.32 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.